QIAGEN Launches New CE-Marked Respiratory Four-Plex Panel That Differentiates Between Flu, RSV and SARS-CoV-2

V. (Venlo, Netherlands) has announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.

QIAGEN’s new Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test is a powerful diagnostic tool in the COVID-19 pandemic, especially in influenza like illness (ILI) or “flu” seasons. It leverages the easy-to-use QIAstat-Dx modular cartridge-based system to deliver fast results that require no additional sample preparation. The polymerase chain reaction (RT-PCR) multiplex test detects and differentiates between influenza A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections in about an hour - a vital capability in the fight against the COVID-19 pandemic. The viruses produce similar respiratory symptoms, making it challenging to clinicians to diagnose exactly which one a patient is suffering from to make the right treatment decisions.

“This new test expands the capabilities of our QIAstat-Dx system with a much-needed COVID-19 application that differentiates between respiratory infections quickly without lab infrastructure,” said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. “With flu season and COVID-19 case numbers still high, this test provides a crucial tool that can be used close to patients and in decentralized environments like ICUs, emergency rooms and satellite labs. By adding this new test to our growing QIAstat-Dx testing menu, we are taking another step to increase the platform’s value for customers beyond the pandemic.”

Related Links:
QIAGEN N.V.